CVRx Barostim BENEFIT-HF rationale: expanding baroreflex activation therapy from LVEF ≤35% to ≤50% heart failure

Preview

CVRx published the scientific rationale for BENEFIT-HF — the 2,500-patient randomized controlled trial expanding Barostim baroreflex activation therapy from the current heart failure indication (LVEF ≤35%) to an expanded population including patients with…